Sandoz Group AG
SDZ.SW
Get informed when a big investor buys or sells
+ FollowMarket Cap$35.85B
Close$
Share Statistics
| Market cap | $35.85 Billion |
|---|---|
| Enterprise Value | $40.81 Billion |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | 7.75% |
|---|---|
| Return on Assets | 3.06% |
| Return on Invested Capital | 14.36% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2.1 |
| Enterprise Value to EBIT | 19.66 |
| Enterprise Value to Net Income | 58 |
| Total Debt to Enterprise | 0.15 |
| Debt to Equity | 0.69 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$1.41
Average shareholder expectationRevenue Estimate
$4.66 B
Average shareholder expectationNext Earnings Call
Expected Date
February 17, 2027
EPS Estimate
$1.88
Average shareholder expectationRevenue Estimate
$5.31 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Sandoz Group AG
22,049 employees
CEO: Mr. Richard Saynor Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. It develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides prot...